Skip to main content
Signal8

NextCure, Inc. (NXTC) Form 8-K — Nov 20, 2026

$NXTCForm 8-KItems 3.01Filed Nov 20, 2026, 7:30 AM ET0001104659-26-130409Original filing

NextCure received a Nasdaq notice on November 16, 2026 stating it is not in compliance with the Global Select Market minimum stockholders' equity requirement, reporting equity of $5.5 million versus the required $10.0 million minimum. The company has until January 4, 2027 to submit a compliance plan, but believes its proposed merger with Avere Therapeutics, expected to close in mid-December 2026 pending stockholder approval, would restore compliance and may eliminate the need for a plan.

Key figures

Stockholders Equity
5503000
Grace period days
45
Compliance plan deadline
January 4, 2027
Minimum stockholders equity required
$10.0 million

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.